Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Theriva Biologics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- 0 vs. Q4 2023
- Shares held
- 791.8K
- −260.4K (−24.7%) vs. Q4 2023
- Total value
- $366.3K
- −$85.9K (−19.0%) vs. Q4 2023
- New holders
- 4
- 4 more added
- Sold out
- 4
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 225,271 | $105.7K | 0.00% | −141,309−38.5% | Reduced |
| BlackRock Inc. | 189,181 | $88.7K | 0.00% | −879−0.5% | Reduced |
| Geode Capital Management, LLC | 141,168 | $66.2K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 68,510 | $32.0K | 0.00% | +9,300+15.7% | Added |
| State Street Corp | 48,691 | $22.8K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 26,599 | $12.5K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 24,679 | $11.6K | 0.00% | −33,274−57.4% | Reduced |
| Two Sigma Securities, LLC | 21,273 | $9.98K | 0.00% | +21,273 | New |
| Charles Schwab Investment Management Inc | 13,566 | $6.36K | 0.00% | 00.0% | Unchanged |
| Lincoln National Corp | 11,000 | $5.16K | 0.00% | 00.0% | Unchanged |
| Blair William & Co | 10,153 | $4.76K | 0.00% | 00.0% | Unchanged |
| Iron Horse Wealth Management, LLC | 365 | $171 | 0.00% | +365 | New |
| IFP Advisors, Inc | 296 | $139 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 233 | $109 | 0.00% | +2+0.9% | Added |
| Tower Research Capital LLC (TRC) | 145 | $68 | 0.00% | 00.0% | Unchanged |
| Old Point Trust & Financial Services N A | 100 | $47 | 0.00% | +100 | New |
| Advisor Group Holdings, Inc. | 47 | $21 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 15 | $7 | 0.00% | −500−97.1% | Reduced |
| Steward Partners Investment Advisory, LLC | 14 | $7 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 10 | $5 | 0.00% | +1+11.1% | Added |
| Bank of America Corp | 6 | $3 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $1 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 9 | $0 | 0.00% | +2+28.6% | Added |
| SageView Advisory Group, LLC | 10,429 | – | – | +10,429 | New |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −47,559−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −39,121−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −28,528−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,712−100.0% | Sold out |